Related references
Note: Only part of the references are listed.Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents
Stephen N. Davis et al.
DIABETES CARE (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes
A. Schweizer et al.
DIABETIC MEDICINE (2007)
Reduced incretin effect in type 2 diabetes - Cause or consequence of the diabetic state?
Filip K. Knop et al.
DIABETES (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
V. Fonseca et al.
DIABETOLOGIA (2007)
Dipeptidyl peptidase-4 inhibitors -: Clinical data and clinical implications
Bo Ahren
DIABETES CARE (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - A randomized trial
Bernard Zinman et al.
ANNALS OF INTERNAL MEDICINE (2007)
Diabetes mellitus and heart failure: Epidemiology, mechanisms, and pharmacotherapy
Frederick A. Masoudi et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial
Julio Rosenstock et al.
DIABETES CARE (2007)
Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris
Whady Hueb et al.
CORONARY ARTERY DISEASE (2007)
Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association
John B. Buse et al.
CIRCULATION (2007)
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
John B. Buse et al.
CLINICAL THERAPEUTICS (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
George G. Sokos et al.
JOURNAL OF CARDIAC FAILURE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Gary A. Herman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2006)
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2006)
Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts
Tingcun Zhao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
LA Nikolaidis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits
DM Flynn et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure
DT Eurich et al.
DIABETES CARE (2005)
Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction - Insights from the National Heart Care Project
SE Inzucchi et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
MD Gorrell
CLINICAL SCIENCE (2005)
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes
A Ceriello et al.
DIABETES CARE (2005)
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure - An observational study
FA Masoudi et al.
CIRCULATION (2005)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model
AK Bose et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
Insulin-treated dia betes is associated with a marked increase in mortality in patients with advanced heart failure
S Smooke et al.
AMERICAN HEART JOURNAL (2005)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes
S Ogawa et al.
DIABETES OBESITY & METABOLISM (2004)
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
LA Nikolaidis et al.
CIRCULATION (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium
U Quast et al.
DIABETES (2004)
Pramlintide for the treatment of insulin-requiring diabetes mellitus - Rationale and review of clinical data
DF Kruger et al.
DRUGS (2004)
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
B Ahrén et al.
DIABETES CARE (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
JJ Meier et al.
HEART (2004)
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial
RE Ratner et al.
DIABETIC MEDICINE (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure - A consensus statement from the American Heart Association and American Diabetes Association
RW Nesto et al.
CIRCULATION (2003)
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial
JL Chiasson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure - The JNC 7 Report
AV Chobanian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes - A 1-year randomized controlled trial
PA Hollander et al.
DIABETES CARE (2003)
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps
C Levetan et al.
DIABETES CARE (2003)
beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes
AE Butler et al.
DIABETES (2003)
Addition of pramlintide to insulin therapy lowers HbA(1c) in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets
P Hollander et al.
DIABETES OBESITY & METABOLISM (2003)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Myocardial infarction in diabetic vs non-diabetic subjects - Survival and infarct size following therapy with sulfonylureas (glibenclamide)
A Klamann et al.
EUROPEAN HEART JOURNAL (2000)
Share Paper
